Trial · NCT07908875
Upfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
NCT07908875, Phase 3, Not yet recruiting, First Affiliated Hospital of Wannan Medical College
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Upfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Trials, record NCT07908875. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908875
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Upfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
- NCT number
- NCT07908875
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 520 participants, estimated
- Lead sponsor
- First Affiliated Hospital of Wannan Medical College
- Conditions
- Ischemia Stroke, TIA (Transient Ischemic Attack)
- Interventions
- Atorvastatin, Hybutimibe 10mg QD
- First posted
- 2026-11-02
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of patients achieving the LDL-C target at 8 weeks | at 8 weeks | Defined as achieving an LDL-C level of \<1.8 mmol/L and a reduction of ≥50% from baseline |
| Secondary | Percentage change in the lipid profile at 8 weeks | at 8 weeks | Evaluated by the least squares mean percentage change from baseline in LDL-C, non-HDL-C, TG, TC, Lp(a), and ApoB. |
| Secondary | Percentage of patients achieving the general LDL-C target at 8 weeks | at 8 weeks | Defined as achieving an LDL-C level of \<1.8 mmol/L at 8 weeks |
| Secondary | Incidence of composite vascular events at 8 weeks | at 8 weeks | Including stroke (ischemic or hemorrhagic stroke), myocardial infarction, and cardiovascular death. |
| Secondary | All-cause mortality rate at 8 weeks | at 8 weeks | Incidence of death from any cause during the study period |
| Secondary | Stroke recurrence rate at 8 weeks | at 8 weeks | Incidence of recurrent stroke events during the follow-up period |
| Secondary | Percentage of patients with a favorable functional outcome at 8 weeks | at 8 weeks | Defined as a modified Rankin Scale (mRS) score of 0 to 2 |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 up to 8 weeks | Up to 8 weeks | Defined as the occurrence of any of the following prespecified safety events: study drug discontinuation or dose reduction due to intolerance, newly diagnosed diabetes, muscle-related adverse events (myalgia, myopathy, muscle necrosis), elevated liver enzymes (ALT or AST \> 3 times the upper limit of normal), or major bleeding events. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908875
GET https://conductscience.org/api/trials/v1/NCT07908875/registered